

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**STA – Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID1648]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The company stated that the appraisal should be clear in the description of its population to ensure no one eligible misses out on treatment. It also stated a recommendation for dapagliflozin would help ensure equality of access without relying on specialist care.

Furthermore, in the consultation on the scope for the ongoing appraisal for empagliflozin for chronic heart failure with preserved or mildly reduced (ID3945), it was stated that socio-economic class, sex, age and race are risk factors for the development of heart failure, and that socio-economic status also has an impact on access to secondary care in the UK, and subsequently access to heart failure treatments.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Differences in the prevalence cannot be addressed in a technology appraisal.

The committee will consider whether its recommendations could have a detrimental impact on people protected by the equality legislation. The committee may also take into account other socio-economic factors using NICE's [manual](#) and [principles](#).

|  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No changes were made to the draft scope to highlight any potential equality issues.      |

|  |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| No additional stakeholders related to potential equality issues were identified during the scoping process   |

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 12 July 2022